• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.

作者信息

Robak Ewa, Jesionek-Kupnicka Dorota, Stelmach Piotr, Kupnicki Piotr, Szataniak Magdalena, Robak Tadeusz

机构信息

Department of Dermatology, Medical University of Lodz, Lodz, Poland.

Department of Pathology, Medical University of Lodz, Lodz, Poland.

出版信息

Ann Hematol. 2022 Jun;101(6):1387-1392. doi: 10.1007/s00277-022-04753-7. Epub 2022 Feb 21.

DOI:10.1007/s00277-022-04753-7
PMID:35187604
Abstract
摘要

相似文献

1
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.加速期慢性淋巴细胞白血病中的皮肤白血病：维奈克拉和利妥昔单抗治疗成功
Ann Hematol. 2022 Jun;101(6):1387-1392. doi: 10.1007/s00277-022-04753-7. Epub 2022 Feb 21.
2
[Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].布鲁顿酪氨酸激酶（BTK）抑制剂、维奈克拉和利妥昔单抗治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):247-250. doi: 10.3760/cma.j.issn.0253-2727.2023.03.012.
3
Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases.维奈托克和利妥昔单抗治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的真实世界疗效：对9例日本患者的回顾性分析。
J Clin Exp Hematop. 2024;64(2):152-155. doi: 10.3960/jslrt.24014.
4
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).维奈克拉治疗伴有del(17p)的复发慢性淋巴细胞白血病患者的难治性自身免疫性溶血性贫血
Ann Hematol. 2017 Sep;96(9):1577-1578. doi: 10.1007/s00277-017-3039-1. Epub 2017 Jun 9.
5
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中 Venetoclax 治疗与微小残留病动力学的综合机制模型。
Clin Pharmacol Ther. 2021 Feb;109(2):424-432. doi: 10.1002/cpt.2005. Epub 2020 Sep 6.
6
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Venetoclax 联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病患者的暴露-反应分析：来自 1b 期研究和 3 期 MURANO 研究的汇总结果。
Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24.
7
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.一项评估 Venetoclax（一种 BCL-2 抑制剂）在复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤日本患者中的 1/2 期研究。
Int J Hematol. 2021 Mar;113(3):370-380. doi: 10.1007/s12185-020-03024-3. Epub 2020 Oct 23.
8
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.GAIA/CLL13研究为维奈克拉在慢性淋巴细胞白血病中的应用提供了进一步的见解。
Lancet Oncol. 2024 Jun;25(6):685-687. doi: 10.1016/S1470-2045(24)00260-2.
9
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.在初治的TP53基因异常的慢性淋巴细胞白血病患者中持续使用维奈托克：一项慢性淋巴细胞白血病领域研究
Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.
10
Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia.在维奈克拉诱导的慢性淋巴细胞白血病不可检测的微小残留病中，因边缘区细胞血管瘤病导致的持续性脾肿大。
Ann Hematol. 2023 Mar;102(3):681-682. doi: 10.1007/s00277-022-05067-4. Epub 2022 Dec 21.

引用本文的文献

1
A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis.癌症治疗的新时代：靶向蛋白酶体 - Bcl - 2轴。
J Exp Clin Cancer Res. 2025 Aug 21;44(1):246. doi: 10.1186/s13046-025-03505-5.
2
Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.加速期慢性淋巴细胞白血病——波兰成人白血病研究组的特征及回顾性分析
Contemp Oncol (Pozn). 2025;29(1):28-35. doi: 10.5114/wo.2025.149235. Epub 2025 Apr 9.
3
"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel therapies.

本文引用的文献

1
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL).白血病皮肤表现作为慢性淋巴细胞白血病（CLL）的早期表现或复发表现。
Acta Biomed. 2021 May 12;92(2):e2021192. doi: 10.23750/abm.v92i2.10763.
“加速型”慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）：在新型疗法时代解析CLL/SLL的生物学灰色地带
Virchows Arch. 2025 Apr;486(4):739-750. doi: 10.1007/s00428-024-03920-7. Epub 2024 Sep 7.
4
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.慢性淋巴细胞白血病的髓外和结外表现——最新进展。
Ann Hematol. 2024 Sep;103(9):3369-3383. doi: 10.1007/s00277-024-05854-1. Epub 2024 Jul 25.
5
Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy.释放BCL-2相关蛋白家族的治疗潜力：探索BCL-2抑制剂在癌症治疗中的应用。
Biomol Ther (Seoul). 2024 May 1;32(3):267-280. doi: 10.4062/biomolther.2023.149. Epub 2024 Apr 9.
6
Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment.皮肤白血病——关于发病机制、诊断和治疗的当前观点
Cancers (Basel). 2023 Nov 13;15(22):5393. doi: 10.3390/cancers15225393.